Barbara Klencke, Sierra Oncology CMO
With an assist from AstraZeneca, the salvage crew at Sierra bets another $216M they can resurrect an old Gilead JAK drug
Almost a decade ago, Gilead shelled out $510 million in cash for YM BioSciences and its only drug, a JAK inhibitor for a rare type …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
